We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
51
Nuveen
North Carolina
$2.18M +$1.29M +81,062 +119%
JF
52
Jump Financial
Illinois
$2.16M +$2.36M +147,850 New
EI
53
EAM Investors
California
$2.02M +$2.2M +138,148 New
JP Morgan Chase
54
JP Morgan Chase
New York
$1.95M +$1.83M +114,502 +374%
Victory Capital Management
55
Victory Capital Management
Texas
$1.88M +$2.05M +128,352 New
Squarepoint
56
Squarepoint
New York
$1.81M +$304K +19,076 +18%
TD Asset Management
57
TD Asset Management
Ontario, Canada
$1.81M +$1.97M +123,738 New
Rafferty Asset Management
58
Rafferty Asset Management
New York
$1.65M +$206K +12,884 +13%
TE
59
Tema ETFs
New York
$1.58M +$448K +28,077 +35%
TI
60
Tidal Investments
Wisconsin
$1.58M +$1.72M +107,775 New
ACM
61
Aquatic Capital Management
Illinois
$1.5M +$1.63M +102,364 New
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.49M +$1.35M +84,282 +482%
FMI
63
F/M Investments
District of Columbia
$1.46M +$1.6M +100,029 New
Raymond James Financial
64
Raymond James Financial
Florida
$1.46M -$340K -21,274 -18%
VOYA Investment Management
65
VOYA Investment Management
Georgia
$1.46M +$1.15M +71,970 +260%
ACM
66
ADAR1 Capital Management
Texas
$1.29M -$6.03M -377,974 -81%
PBM
67
Propel Bio Management
California
$1.25M +$1.37M +85,791 New
Connor, Clark & Lunn Investment Management (CC&L)
68
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.23M +$890K +55,790 +198%
SFCM
69
Seven Fleet Capital Management
California
$1.21M +$1.32M +82,890 New
Renaissance Technologies
70
Renaissance Technologies
New York
$1.19M +$1.3M +81,310 New
RhumbLine Advisers
71
RhumbLine Advisers
Massachusetts
$1.12M +$92.4K +5,787 +8%
TL
72
TowerView LLC
New York
$1.02M -$1.12M -70,000 -50%
Acadian Asset Management
73
Acadian Asset Management
Massachusetts
$1.01M +$1.1M +69,152 New
AA
74
ALPS Advisors
Colorado
$998K +$110K +6,876 +11%
JSC
75
Jackson Square Capital
California
$933K – – –
1 2
3
4 5

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.